ERYTECH announces fast take-off of its Phase IIb study in Acute Myeloid Leukemia Post author:admERY Post published:July 4, 2013 Post category:Newsroom ERYTECH announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia (AML). You Might Also Like ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018 June 15, 2018 ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer September 20, 2018 ERYTECH extends its cash horizon by implementing a convertible bond financing June 25, 2020
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018 June 15, 2018
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer September 20, 2018
